STAFFORD, Texas – (COMMERCIAL THREAD) – Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the âCompanyâ), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent recurrence of breast cancer in patients who have previously undergone surgery, today provides investors with its up-to-date company presentation and recent webcasts.
A webcast of the company’s updated corporate presentation with commentary from CEO Snehal Patel is available in the investors section of the company’s website. here.
Mr. Patel commented, âWe are very pleased to present the combined analysis of our 5-year Phase IIb data from our recently released single timeline posters, and we look forward to more publications to come. The integrated analysis of efficacy, immune response and safety data has attracted the interest of large institutions, including large institutional investors in pharmaceuticals, regional pharmaceuticals and biotechnology, which we present at investor and partnership conferences. international. We discussed a possible license of GP2, new investment banking partners, collaboration in our Phase III clinical trial, commercial manufacturing, expansion of our pipeline, expansion of our trials clinical trials in Europe and the launch of additional phase II / III GP2 trials.
Additional webcasts of Mr. Patel’s participation in a Benzinga cancer panel and a TD Ameritrade interview can be viewed at the links below:
On September 30, 2021, Mr. Patel participated in a live panel discussion at the Benzinga Healthcare Small-Cap conference titled: Immuno-Oncology – Harnessing the Human Body’s Power to Battle Cancer. A webcast of the full roundtable can be viewed here with Mr. Patel speaking at the times available on these links: 2:15, 18:03, and 34:00.
On July 20, 2021, Mr. Patel appeared as a featured guest in a live interview on the TD Ameritrade Network show. Watchlist with host Nicole Petallides. A webcast of the interview can be viewed here.
About Breast Cancer and HER2 /new Positivity
One in eight American women will develop invasive breast cancer in her lifetime, with an estimated 282,000 new breast cancer patients and 3.8 million breast cancer survivors in 2021. HER2 /new (human epidermal growth factor receptor 2) is a cell surface receptor protein that is expressed in a variety of common cancers, including 75% of breast cancers at low (1+), intermediate (2+) and high (3+ or over-expressing).
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrence in patients with previous surgery. GP2 is a 9 amino acid transmembrane peptide of HER2 /new protein. In a randomized, single-blind, placebo-controlled, multicenter (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrence was observed in the HER2 /new Adjuvant 3+ setting after 5 years of median follow-up, if the patient received the 6 primary intradermal injections during the first 6 months (p = 0.0338). Of the 138 patients who have been treated with GP2 to date in 4 clinical trials, treatment with GP2 has been well tolerated and no serious adverse events have been observed related to GP2 immunotherapy. Greenwich LifeSciences plans to begin a Phase III clinical trial using a treatment regimen similar to that of the Phase IIb clinical trial. For more information on Greenwich LifeSciences, please visit the company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.
About the immune response of GP2 immunotherapy
As previously reported, GP2 immunotherapy generated immune responses specific to GP2, leading to no recurrence of metastatic breast cancer in HER2 /new 3+ population in the Phase IIb clinical trial, thus supporting the mechanism of action of GP2. A statistically significant peak in immunity was achieved after 6 months of treatment with GP2, as measured by both the Dimer Binding Assay and the DTH skin test. HER2 /new The immune response of the 3+ population was similar to that of HER2 /new Immune response of the 1-2+ population, suggesting potential to treat HER2 /new Population 1-2+ (including triple negative breast cancer) with GP2 immunotherapy in combination with trastuzumab (Herceptin) products and other clinically active agents. Broad-based immune response suggests the potential of GP2 to treat other HER2 /new 1-3 + expressing cancers. For more information on the GP2 immune response and clinical data, please visit the Company’s Clinical Trials tab at https://greenwichlifesciences.com/clinical-trials/.
Disclaimer regarding forward-looking statements
The statements contained in this press release contain “forward-looking statements” which are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate”, “believe”, “contemplate”, “might”, “estimate”, “expect”, “have the intention â,â seek, âmayâ, âcouldâ, âplanâ, âpotentialâ, âpredictâ, âplanâ, âtargetâ, âaimâ, âshouldâ, âwillâ, âwouldâ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the current expectations of Greenwich LifeSciences Inc. and are subject to inherent uncertainties, risks and difficult-to-predict assumptions, including statements regarding the intended use of the net proceeds of the public offering; therefore, actual results may differ materially from those expressed or implied by such forward-looking statements. In addition, certain forward-looking statements are based on assumptions about future events which may not prove These and other risks and uncertainties are more fully described in the section entitled “Risk Factors” in the final prospectus. relating to the public offering filed with the SEC. The forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. assumes no obligation to update such information, except as required by applicable law.